the Effect of Broken Ganoderma Lucidum Spore Powder on Quality of Life and Immune Function in Patients With Diffuse Large B-cell Lymphoma After Chemotherapy
NCT ID: NCT04914143
Last Updated: 2021-06-04
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
120 participants
INTERVENTIONAL
2020-06-06
2023-12-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study of Improving the Efficacy of Treatment in Diffused Large B Cell Lymphoma Patients
NCT01793844
Lenalidomide Plus ICE in the Treatment of Refractory and Relapsed DLBCL
NCT03367143
Modified BFM-95 Regimen as First-Line Chemotherapy in Adults With T- Lymphoblastic Lymphoma
NCT02396043
Zanubrutinib-based Maintenance Therapy of Newly Diagnosed DLBCL With Initial Remission
NCT06669143
Relmacabtagene Autoleucel in Patients With LBCL
NCT06142175
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Experimental group
broken Ganoderma lucidum spore powder
The experimental group was treated with broken Ganoderma lucidum spore powder after chemotherapy
placebo comparator group
placebo
the control group was treated with placebo after chemotherapy
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
broken Ganoderma lucidum spore powder
The experimental group was treated with broken Ganoderma lucidum spore powder after chemotherapy
placebo
the control group was treated with placebo after chemotherapy
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* all patients were diagnosed for the first time
* between 18-75 years old, male and female
* ECoG 0-3 ，the expected survival was more than 6 months
* the pregnancy test of women of childbearing age was negative; Male and female patients should agree to take effective contraceptive measures during the treatment period and one year of follow-up;
* sign the informed consent before the test screening
Exclusion Criteria
* uncontrolled psychosis
* participating in other trials at the same time, and using experimental drugs that may affect the efficacy and safety evaluation
* impairment of liver and kidney function
* HIV antibody positive;
* HBsAg positive hepatitis B carriers and confirmed hepatitis B and C patients;
* pregnant or lactating women and patients who do not agree to take effective contraceptive measures;
* the patient is unable to swallow the capsule or has a disease or condition that seriously affects the gastrointestinal function;
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Second Affiliated Hospital, School of Medicine, Zhejiang University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
yun liang
Role: PRINCIPAL_INVESTIGATOR
2ndAffiliated Hospital, School of Medicine, Zhejiang University, China
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
2ndAffiliated Hospital, School of Medicine, Zhejiang University, China
Hangzhou, Zhejiang, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2020-261
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.